| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/50-1/100 | Human,Mouse,Rat |
| ICC | 1/100-1/200 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | Double minute 2 protein; Hdm2; Oncoprotein Mdm2 |
| Entrez GeneID | 4193 |
| WB Predicted band size | Calculated MW: 55 kDa; Observed MW: 90 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human,Rat |
| Immunogen | Synthetic peptide of human MDM2 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide,0.5%BSA and 50% glycerol. |
+ +
以下是3篇关于MDM2抗体的经典文献及其摘要概括：
---
1. **文献名称**：*Inhibition of the p53-MDM2 interaction: Targeting a key hotspot for drug discovery*
**作者**：Vassilev, L.T. et al.
**摘要**：该研究通过筛选小分子抑制剂，开发了选择性靶向MDM2-p53结合界面的化合物，并利用MDM2特异性抗体验证了抑制剂对MDM2-p53复合物结合的阻断作用，为癌症治疗提供新策略。
---
2. **文献名称**：*Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain*
**作者**：Kussie, P.H. et al.
**摘要**：通过X射线晶体学解析了MDM2与p53转录激活结构域复合物的三维结构，使用特异性抗体定位关键结合区域，揭示了MDM2如何通过疏水口袋结合p53.为设计靶向抗体或药物奠定基础。
---
3. **文献名称**：*MDM2 is a central node in the feedback regulation of p53 signaling*
**作者**：Honda, R. et al.
**摘要**：研究阐明了MDM2通过泛素-蛋白酶体通路调控p53降解的分子机制，利用MDM2抗体进行免疫共沉淀实验，证实其E3泛素连接酶活性对p53稳态的关键作用。
---
以上文献均聚焦于MDM2的功能研究及其实验工具(如抗体)的应用，涉及结构、调控机制及治疗靶点开发。如需扩展，可补充肿瘤模型中MDM2抗体治疗的研究(如Nature Medicine等期刊论文)。
The MDM2 (mouse double minute 2 homolog) protein, an E3 ubiquitin ligase, plays a pivotal role in regulating the tumor suppressor p53. Under normal conditions, MDM2 binds to p53. promoting its ubiquitination and subsequent proteasomal degradation, thereby maintaining low p53 levels to prevent excessive cell cycle arrest or apoptosis. This feedback loop ensures cellular homeostasis. However, MDM2 overexpression—often due to gene amplification or transcriptional upregulation—disrupts this balance, leading to p53 inactivation and uncontrolled cell proliferation, a hallmark of many cancers, including sarcomas and gliomas.
MDM2 antibodies are essential tools for studying its expression, localization, and interaction with p53 in research and diagnostics. They enable detection via techniques like immunohistochemistry (IHC) and Western blot, aiding in cancer profiling and prognostic assessments. Therapeutically, MDM2 is a promising target, with inhibitors and monoclonal antibodies in development to block MDM2-p53 interactions, restore p53 activity, and trigger tumor cell death. Challenges remain in achieving specificity and avoiding off-target effects, but ongoing preclinical and clinical trials highlight its potential in precision oncology. MDM2 antibodies thus bridge basic research, diagnostic applications, and novel therapeutic strategies in cancer.
×
